The Label Says 600 Milligrams. Nine Bottles Assayed; The Median Was 96.
Crews on the Nevada fire lines take a capsule sold as protection against smoke. We bought nine bottles from four sellers and had them assayed blind. Two contained none of the compound at all.
A months-long reporting project. Documents cited below are held in The Vault and available to readers.
RENO, Nevada — Two of the nine bottles contain none of it.
Not a low dose. None — nothing at or above the laboratory's limit of detection, which is eight milligrams a capsule. The label on both says six hundred.
One of those two we bought from a marketplace seller. The other we bought from the manufacturer's own storefront, on the twenty-second of July, and it arrived in four days.
What crews are taking
Fire camps are their own economy, and this season the item moving through it is a plain white capsule sold as protection for the lungs against smoke.
It is not a prescription. It is not a drug. It is a dietary supplement, which in the United States means that nobody checks what is in the bottle before it is sold, and nobody has to.
Ruthann Begay-Trosclair runs a hand crew. She has bought the capsules for three seasons, out of her own pocket, and hands them round at morning briefing without a word about what they do.
"I am not a doctor and I do not tell them it works," she said. "I tell them it is there. That is the honest version and they can take it or leave it."
What we did with them
We bought nine bottles from four sellers over one week in July, at retail, with receipts.
We took the labels off, gave each bottle a number, and sent all nine to a contract laboratory in Sacramento. The laboratory was told they were dietary capsules. It was not told what they were meant to contain, who made them, or what anybody hoped it would find.
Every bottle claims six hundred milligrams a capsule.
The median measurement across the nine is ninety-six.
The best bottle in the set is 214, which is a third of the claim. Then 168, then 141, then two at 96, then 71, then 44, then the two with nothing in them.
The compound itself
The molecule is real, it is old, and it is not exotic. It is a precursor to a compound the lung uses to mop up the products of oxidation, and inhaled smoke produces a great many of those.
The legend on the fire line is that it was issued to workers at a weapons test site in the nineteen-seventies and then quietly taken away. That is very nearly true, and this desk spent a month establishing which part of it is not.
It was issued. The cohort is 341 men. There is a mortality difference and nobody has explained it.
The comparison group was assembled afterwards, from a different payroll, by somebody who already knew how the first group had done. Dr. Marguerite Oyibo-Halvorsen, a respiratory pharmacologist who read the whole file for us, put it plainly.
"That is not a control group," she said. "That is a group of people who were available. I would love this to be evidence. It is a reason to run a trial, and it has been a reason to run a trial for fifty-two years."
The two trials that do exist
There are two randomised trials. One has 60 participants and one has 88.
The larger one is negative on its primary endpoint and positive on a secondary one, which is the shape of result that has misled this newspaper before and which we now write out in full whenever we meet it.
The confidence interval on the positive secondary endpoint crosses no effect at one end and a clinically interesting effect at the other. It is compatible with the capsule doing nothing and compatible with the capsule mattering.
"Nobody should be selling anything on the back of that," Oyibo-Halvorsen said. "And nobody should be dismissing it on the back of that either. It is a shrug with error bars."
Who would pay
We wrote to a pharmaceutical sponsor and asked two questions: what would a properly powered trial cost, and would anyone fund it.
The reply is filed as PX-2065 and it is published in full. It is not evasive. It is arithmetic.
A trial large enough to answer the question in a working population would cost somewhere near fourteen million dollars. The compound has been off patent since before most of the crew were born. Any positive result would be immediately available to every manufacturer in the world, including the man with the cupboard in Ogden.
The letter's last paragraph says the company would look again if a public body put up half. No public body has been asked, because no one has the job of asking.
What this desk takes from it
The official warning that put this on the wire is correct as far as it goes: crews are taking an unregulated capsule at unknown dose for an unproven purpose, and two of the nine bottles we bought were empty of it.
But the warning tells a crew boss what not to do and offers her nothing instead, and she will be on a line again next August with the same six hundred hours of smoke ahead of her.
The bottle is the story we could prove. The trial that does not exist is the story we could only describe.
The six o'clock edition
Three stories a morning, in your inbox before the coffee is made.
Sources & Method
We did not ask anybody what is in the capsules. We bought them — nine bottles, four sellers, at retail, over one week, with the receipts published — and sent them to a contract laboratory under numbers, telling it only that they were dietary capsules. Then we did the slower half: we read both randomised trials and the historical cohort with a respiratory pharmacologist who was not told what we expected, and we wrote to the one company that could afford the trial that would settle it, and printed its answer.
Who we spoke to
- Denny Pouliot-Sackville, Founder, Ashfall Labs; formerly a hotshot crew member. Interviewed by telephone twice and in person at his premises; reply printed in full July and August 2026 Accepts our assay figures. Produced a recall notice we were able to date-check.
- Kestrel Analytical, Sacramento, Contract laboratory. Commissioned and paid by this newspaper; told only that the samples were dietary capsules, and not what result any party hoped for Certificates dated 29 July to 6 August 2026 All nine certificates are published on this page, including the method and the limit of detection.
- Dr. Marguerite Oyibo-Halvorsen, Respiratory pharmacologist. Interviewed by video call three times; read both randomised trials and the historical cohort at our request June–August 2026 Believes the compound is worth testing properly and that the evidence for it is currently very thin.
- Ruthann Begay-Trosclair, Crew boss, a hand crew working the Nevada fires. Interviewed on the line at a spike camp, and again by telephone a week later August 2026 Buys the capsules for her crew out of her own money and has done for three seasons.
- A pharmaceutical sponsor, Declining letter, filed as PX-2065. Written enquiry from this newspaper asking what a phase III would cost and whether anyone would fund it; reply published in full May 2026 The letter is unusually candid about why the answer is no.
Documents
- PX-2065 — Reply to this newspaper's funding enquiry, from a pharmaceutical sponsor, declining to fund a phase III accepted
What we could not confirm
- Whether the compound does anything at all for smoke exposure. There are two randomised trials, both small, one positive on a secondary endpoint. Dr. Oyibo-Halvorsen would not call that evidence and neither will we.
- The historical cohort. Three hundred and forty-one men, a mortality difference nobody has explained, and a comparison group assembled afterwards from a different payroll. That last fact is enough to sink it and we cannot rescue it.
- Whether our nine bottles are representative of anything. Nine bottles, four sellers, one week, one state. A tenth bottle could have come back at the full 600 mg and we would still have printed the nine.
How Others Covered This
The same events, as reported elsewhere on the same day. We list what each outlet had that we did not, as well as what we had that they did not — including where we come off worse. Why we print this.
-
The Meridian TelegraphTHE PILL THE GOVERNMENT GAVE ITS OWN TEST WORKERS IS BACK ON THE FIRE LINE
Ran the historical cohort as vindication and the official warning as suppression.
Had that we did not
A genuinely good interview with a crew boss about what smoke does to a season.
Left out
That nobody has assayed the capsules; that the phase III does not exist; that the compound is off-patent and therefore has no owner to pay for one.
-
The Hollow PostWHY WON'T THEY LET FIREFIGHTERS HAVE IT
Cover-up framing throughout. Named no laboratory and quoted no pharmacologist.
Had that we did not
Nothing this newspaper could stand up.
Left out
The two bottles containing none of it, which were on sale while that story ran.
-
They Buriedthis newspaperThe Label Says 600 Milligrams. Nine Bottles Assayed; The Median Was 96.
Bought the product at retail and had it assayed blind, then read the underlying trial evidence and asked who would pay for the missing one.
Had that we did not
Nine certificates of analysis in full, the two small randomised trials with their confidence intervals, and a declining letter from the only sponsor who could have funded the answer.
Left out
Our headline is about a bottle. The story is about the fact that no one on earth has a commercial reason to find out whether this works, and that is the harder and more important finding, and it arrives at crosshead six. — V. Ashcombe-Doyle, standards editor
Right of Reply
They Buried contacted Denny Pouliot-Sackville, founder of Ashfall Labs on 11 August 2026 by our reply editor, in writing, with all nine certificates of analysis attached and fourteen days to respond. Replied on 20 August 2026, then telephoned to add a paragraph, which is included where he asked for it. Printed in full and unedited.
Your numbers are right and I already knew they were right, which is the worst answer I can give you and the only true one.
I sent four bottles of the March lot to a laboratory in April, on my own money, because a crew boss in Idaho told me the capsules smelled different. I got back roughly what you got back. I stopped shipping that lot on the 30th of April and I posted a recall on the crew forum where ninety per cent of my customers are, and I refunded everyone who asked, which was sixty-one people out of about four hundred.
What I did not do is post it anywhere a stranger would find it, and I did not pull the bottles that were already sitting in stores, because I did not think I could make anyone take them off a shelf and I did not try hard enough to find out. Two of the nine you bought are mine and are from that lot. That is on me and I am not going to dress it up.
Here is the part I want printed at the same size.
I am one man with a contract filler in Ogden and a fulfilment cupboard. I should be better and I am going to be. But you have spent three months and, I would guess, several thousand dollars establishing that a small operator's quality control is bad, and you spent about a page on the reason my customers came to me in the first place.
I cut line for eleven seasons. In an average season I breathed smoke for somewhere between four hundred and six hundred hours. The instruction I was given for that, every year, by every agency I ever worked for, amounted to: try to stay upwind. That is not a policy. That is weather.
There is a compound that a government thought well enough of, in 1974, to issue to men it was actually worried about. Nobody owns it. It costs forty cents a gram. Two small trials exist and both were done by people paying for them out of a departmental fund, and the trial that would settle it has never been run because there is no one standing at the end of it holding a patent.
So a crew boss in Elko buys my capsules with her own money and hands them out at briefing, and your newspaper's finding is that my capsules are one sixth of what they say. Fine. Correct. Fix that, and she still has nothing, and next August she will breathe the same smoke.
I would rather you had written that story. But I understand that you cannot write it, because you cannot assay an absence, and a bottle is a thing you can hold up.
[Added by telephone, 21 August:] Print the recall date. If it turns out I am wrong about the 30th of April, print that too, and I will send you the invoice from the laboratory so you can check me the way you checked the bottles.
Published unedited under our right-of-reply guarantee.
How was this story?
We publish the result, whatever it is. Reader verdicts appear on the front page and in our newsroom metrics.
Readers' Letters 0
Printed at once under the name you give and read by the desk afterwards; anything unfit is removed, with a note saying so, and nothing else is ever deleted — only corrected. Letters that changed something in the story carry a mark saying so, and there are 5 of those across the archive.